 |
| Global GLP-1 Receptor Agonist Market Size |
The global GLP-1 Receptor Agonist Market is estimated to be valued at US$
14,319.85 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
GLP-1 receptor agonists are injectable drugs used for the treatment of type 2 diabetes.
They work by stimulating the release of insulin from pancreatic beta cells in
response to increased blood glucose levels. This helps regulate blood sugar
levels more efficiently than traditional therapies.
Market key trends:
One of the key trends in the GLP-1 receptor agonist market is the increasing
number of approvals for new drug molecules. Over the past few years, regulatory
agencies like the US FDA have approved several new GLP-1 receptor agonists like
semaglutide, dulaglutide, and albiglutide for the treatment of type 2 diabetes.
The launch of these new drugs has provided more treatment options to physicians
and increased competition in the market. Moreover, several pipeline drugs are
currently under clinical trials which could further drive the growth of the
market during the forecast period if approved.
Segment Analysis
The global GLP-1 receptor agonist market is segmented based on drug type,
application, distribution channel and region. The drug type segment is further
divided into exenatide, liraglutide, lixisenatide, dulaglutide and albiglutide.
Among these, liraglutide holds the largest market share owing to its wide
acceptance and efficacy in managing diabetes. Lixisenatide also holds a
significant share as it helps manage the blood sugar levels conveniently.
Key Takeaways
The Global
GLP-1 Receptor Agonist Market Size is expected to witness high growth,
exhibiting a CAGR of 6.1% over the
forecast period, due to the increasing prevalence of diabetes worldwide.
Regional analysis
North America dominates the global market and is expected to continue its
dominance over the forecast period. This is attributed to the growing diabetic
population and increasing awareness regarding the benefits of GLP-1 receptor
agonist drugs in the region. Asia Pacific shows the highest growth rate owing
to rising healthcare expenditure and growing medical tourism in countries like
India and China.
Key players
Key players operating in the GLP-1 receptor agonist market are Eli Lilly and
Company, GlaxoSmithKline plc, Novo Nordisk, PegBio Co., Ltd., AstraZeneca,
Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm.
Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui
Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.
Get
More Insights On This Topic: https://www.pressreleasebulletin.com/glp-1-receptor-agonist-market-size/